Validation of the FibroScan-AST (FAST) and Agile 3+ score in metabolic dysfunction-associated steatotic liver disease in a Russian cohort of patients

Introduction. The high prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) requires timely diagnosis of its progressive forms. Recently developed for this purpose FibroScan-AST (FAST) and Agile 3+ indices have shown good diagnostic capabilities, but have not been validated in a Russian cohort.

Aim. To evaluate the diagnostic efficiency of the FAST and Agile 3+ scores in Russian patients with MASLD.

Materials and methods. The medical records of 43 patients with histologically verified MASLD and transient elastography (TE) performed were analyzed. Non-invasive indices of progressive MASLD were calculated: FIB-4, FAST and Agile 3+.

Results. All the studied methods demonstrated good diagnostic ability. FAST demonstrated the best results for detecting non-alcoholic steatohepatitis (NASH) + NAS ≥ 4 + F ≥ 2 compared to TE and FIB-4. The area under the ROC curve (AUROC) for FAST was 0.827 ± 0.064 (95% CI: 0.701–0.952, p < 0.0001); for FIB-4 and TE – 0.786 ± 0.069 (95% CI: 0.651–0.920, p = 0.001) and 0.758 ± 0.075 (95% CI: 0.610–0.905, p = 0.004), respectively. However, the standard FAST cutoff values (≤0.35 and ≥0.67) had low sensitivity in the study cohort: the number of indeterminate results was 60.5%. Optimization of the FAST cutoff values (≤0.41 and ≥0.52) reduced the proportion of indeterminate cases to 23.25% and increased the number of correctly classified patients (from 37.2% to 62.8%, p = 0.0012). For the diagnosis of progressive fibrosis (F ≥ 3), the Agile 3+ score showed the best result (AUROC = 0.825 ± 0.077 (95% CI: 0.675–0.976, p = 0.003)) compared to FIB-4 and TE, but recalculation of the threshold values did not lead to a significant improvement in the diagnostic ability of the Agile 3+.

Conclusions. The FAST and Agile 3+ scores are effective for diagnosing progressive MASLD, but the FAST threshold values require adaptation for the Russian population.

1. Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl.):S32–S42. https://doi.org/10.3350/cmh.2022.0365.

2. Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, Paik JM. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol. 2024;22(10):1999–2010. https://doi.org/10.1016/j.cgh.2024.03.006.

3. Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and metaanalysis. Lancet Gastroenter Hepatol. 2023;8(1):20–30. https://doi.org/10.1016/S2468-1253(22)00317-X.

4. Maev IV, Andreev DN, Kucheryavyy YuA. Prevalence of non-alcoholic fat disease liver in Russian Federation: meta-analysis. Consilium Medicum. 2023;25(5):313–319. (In Russ.) https://doi.org/10.26442/20751753.2023.5.202155.

5. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. https://doi.org/10.1097/HEP.0000000000000520.

6. Raikhelson KL, Maevskaya MV, Zharkova MS, Grechishnikova VR, Okovityi SV, Deeva TA et al. Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(2):35–44. (In Russ.) https://doi.org/10.22416/1382-4376-2024-34-2-35-44.

7. Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunctionassociated steatotic liver disease. Eur J Intern Med. 2024;122:3–10. https://doi.org/10.1016/j.ejim.2023.11.005.

8. Saiman Y, Duarte-Rojo A, Rinella ME. Fatty Liver Disease: Diagnosis and Stratification. Annu Rev Med. 2022;73:529–544. https://doi.org/10.1146/annurev-med-042220-020407.

9. Le P, Payne JY, Zhang L, Deshpande A, Rothberg MB, Alkhouri N et al. Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging Studies. Clin Gastroenterol Hepatol. 2023;21(5):1154–1168. https://doi.org/10.1016/j.cgh.2022.07.033.

10. Mantovani A, Csermely A, Petracca G, Beatrice G., Corey KE, Simon TG et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–913. https://doi.org/10.1016/S2468-1253(21)00308-3.

11. Le MH, Le DM, Baez TC, Dang H, Nguyen VH, Lee K et al. Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Mol Hepatol. 2024;30(2):235–246. https://doi.org/10.3350/cmh.2023.0485.

12. Davison BA, Harrison SA, Cotter G, Alkhouri N, Sanyal A, Edwards C et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020;73(6):1322–1332. https://doi.org/10.1016/j.jhep.2020.06.025.

13. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5):1486–1501. https://doi.org/10.1002/hep.29302.

14. Xu X, Jin J, Liu Y. Performance of FibroScan in grading steatosis and fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Arab J Gastroenterol. 2023;24(4):189–197. https://doi.org/10.1016/j.ajg.2023.08.003.

15. Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362–373. https://doi.org/10.1016/S2468-1253(19)30383-8.

16. Younossi ZS, Harrison S, Newsome PN, Chan W, Yilmaz Y, de Ledinghen V et al. Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with nonalcoholic fatty liver disease. J Hepatol. 2021;75:S205–S293.

17. Mallet V, Parlati L, Vallet-Pichard A, Terris B, Tsochatzis E, Sogn P, Pol S. FIB-4 index to rule-out advanced liver fibrosis in NAFLD patients. Presse Med. 2019;48(12):1484–1488. (In French) https://doi.org/10.1016/j.lpm.2019.10.017.

18. McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol. 2017;112(5):740–751. https://doi.org/10.1038/ajg.2016.453.

19. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454–462. https://doi.org/10.1002/hep.23312.

20. Karlas T, Petroff D, Garnov N, Böhm S, Tenckhoff H, Wittekind C et al. Noninvasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PloS ONE. 2014;9(3):e91987. https://doi.org/10.1371/journal.pone.0091987.

21. Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56(5):1751–1759. https://doi.org/10.1002/hep.25889.

22. Sanyal AJ, Foucquier J, Younossi ZM, Harrison SA, Newsome PN, Chan WK et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol. 2023;78(2):247–259. https://doi.org/10.1016/j.jhep.2022.10.034.

23. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082–1090. https://doi.org/10.1002/hep.24452.

24. Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(6):1717–1730. https://doi.org/10.1053/j.gastro.2019.01.042.

25. Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M et al. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019;17(1):156–163.e2. https://doi.org/10.1016/j.cgh.2018.04.043.

26. Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67(5):1754–1767. https://doi.org/10.1002/hep.29477.

27. Ray K. Resmetirom proves positive for NASH with liver fibrosis. Nat Rev Gastroenterol Hepatol. 2024;21(4):218. https://doi.org/10.1038/s41575-024-00909-0.

28. De A, Keisham A, Mishra S, Mehta M, Verma N, Premkumar M et al. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis – Validation in an Indian Cohort. J Clin Exp Hepatol. 2022;12(2):440–447. https://doi.org/10.1016/j.jceh.2021.06.008.

29. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557–1565. https://doi.org/10.1002/hep.29085.

30. Shang Y, Akbar, C, Dodd M, Nasr P, Vessby J, Rorsman F et al. Cause of death by fibrosis stage in 959 patients with biopsy-proven NAFLD. Gut. 2024;73(11):e30. https://doi.org/10.1136/gutjnl-2023-331331.